Patent Claims

1. Cell line DSM ACC3006, or DSM ACC3007, or DSM ACC3008.

2. Antibody obtained from one of the cell lines according to claim 1.

3. Use of an antibody according to claim 2 in an immunoassay.

~~4. Kit comprising~~

~~a) an antibody obtained from cell line DSM ACC2708, or DSM ACC3006, or DSM ACC3007, or DSM ACC3008 as capture reagent,~~

~~b) an antibody obtained from cell line DSM ACC2708, or DSM ACC3006, or DSM ACC3007, or DSM ACC3008 as detection reagent.~~

~~5~~4. Method for detecting a ~~therapeutic~~ human or humanized antibody in a sample obtained from an experimental dog, rhesus-monkey, marmoset, baboon, cynomolgus~~animal~~ comprising the steps of

a) providing the sample to be analyzed,

b) incubating said sample with an antibody ~~binding to the same epitope as an antibody~~ according to claim 2,

c) optionally incubating said sample with a reagent appropriate for the selective detection of total, active or antigen-bound ~~therapeutic~~ human or humanized antibody, and

d) correlating the complex formed in (b) or (c) to the concentration of said ~~therapeutic~~ human or humanized antibody.

~~6~~5. Method for immunologically determining a ~~therapeutic~~ human or humanized antibody in a sample obtained from an experimental dog, rhesus-monkey, marmoset, baboon, cynomolgus~~animal~~ using an antigen bridging immunoassay comprising a capture antibody and a tracer antibody, characterized in that said capture antibody and said tracer antibody are both independently selected from antibodies ~~binding to the same epitope as an antibody~~ according to claim 2.

~~7~~6. Method according to claim ~~6~~5, characterized in that said immunoassay is a sandwich immunoassay.

~~8~~7. Method according to any one of claims ~~6~~5 or ~~7~~6, characterized in that the capture antibody is conjugated to biotin and immobilization is performed via immobilized avidin or streptavidin.

98. Method according to any one of claims 65 to 87, characterized in that the tracer antibody is conjugated to digoxygenin and linking to the detectable label is performed via an antibody against digoxygenin.

109. The method according to any one of claims 5-4 to 98, characterized in that said human or humanizedtherapeutic antibody is a Fab.

11. The method according to any one of claims 5 to 10, characterized in that said experimental animal is selected from the group comprising the members of the families of marmosets and tamarins, old world monkeys, dwarf and mouse lemurs, gibbons and lesser apes, true lemurs, as well as crossings thereof.

12. The method according to any one of claims 5 to 11, characterized in that said therapeutic antibody is a human or a humanized antibody.

1310. Use of an antibody which is binding to a therapeutic human or humanized antibody and not binding to the immunoglobulin of an experimental dog, rhesus-monkey, marmoset, baboon, cynomolgusanimal for measuring the concentration of total, active, or antigen-bound human or humanizedtherapeutic antibody in a sample obtained from an experimental dog, rhesus-monkey, marmoset, baboon, cynomolgusanimal whereby the antibody is binding to the same epitope as an antibody according to claim 2.

1411. Antibody composition, characterized in comprising a mixture of antibodies produced by the cell line DSM ACC3006, the cell line DSM ACC3007, the cell line DSM ACC3008.

1512. Use of an antibody composition according to claim 14-11 in a method according to any one of claims 5-4 to 129.

1613. Antibody binding to human or chimpanzee IgG and not binding to canine and marmoset IgG, characterized in that the K_D-value for binding to a human or chimpanzee IgG is 10^{-9} mol/l or less.

1714. The antibody according to claim 1613, characterized in that the antibody is not binding to canine, Rhesus-monkey, marmoset, baboon, and cynomolgus IgG, characterized in that the K_D-value for binding to canine, Rhesus-monkey, marmoset, baboon, and cynomolgus IgG is 10^{-6} mol/l or more.

18. The antibody according to any one of claims 16 to 17, characterized in that the K_D-value for binding to a human or chimpanzee IgG is 10^{-9} mol/l or less and the K_D-value for binding to canine, Rhesus-monkey, marmoset, baboon, and cynomolgus IgG is 10^{-6} mol/l or more.

~~19~~15. The antibody according to any one of claims 16 to 18, characterized in that the antibody is a monoclonal antibody.

~~20. Antibody specifically binding to an IgG1 that comprises a kappa light chain constant domain.~~

~~21. The antibody according to claim 20, characterized in that the antibody is further binding to an IgG2.~~

~~22. The antibody according to any one of claims 20 to 21, characterized in that the antibody is further binding to an IgG4.~~

~~23. The antibody according to any one of claims 20 to 22, characterized in that the antibody is not binding to an IgG3.~~

~~24. The antibody according to any one of claims 20 to 23, characterized in that the antibody is not binding to an IgG1 that comprises a lambda light chain constant domain.~~

~~25. The antibody according to any one of claims 20 to 24, characterized in that the antibody is a monoclonal antibody.~~

~~26~~16. Use of an antibody according to any one of claims ~~16~~ 13 to ~~25~~ 15 in a method according to any one of claims ~~5~~ 4 to ~~12~~9.